Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Celgene Seeks Additional Oncologic To Leverage Thalomid Sales Force

Executive Summary

Celgene is planning to in-license an oncology product to be detailed alongside Thalomid (thalidomide), CEO John Jackson told the Biotechnology Industry Organization's CEO & Investor Conference in New York City Feb. 21.

You may also be interested in...

Signal Chooses Acquisition By Celgene Over Initial Public Offering

Signal Pharmaceuticals has chosen to accept an acquisition offer from Celgene instead of going through with an initial public offering, the companies said in a June 30 analysts call announcing the merger.

Celgene Thalomid Promotions For Off-Label Cancer Use Draw FDA Warning

Thalomid sales representatives have disseminated third-party press releases that promote off-label use of the thalidomide capsules for multiple myeloma, an FDA warning letter to Celgene states.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts